Cargando…

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer

Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer’s most prominent genetic alterations. Its mutation could generate various effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halim, Freda, Azhar, Yohana, Suwarman, Suwarman, Hernowo, Bethy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718986/ https://www.ncbi.nlm.nih.gov/pubmed/36519010 http://dx.doi.org/10.12688/f1000research.108628.2

Ejemplares similares

Positive p53 Expression Is Associated with Primary Endocrine Therapy Resistance in Locally Advanced Stage Luminal B HER2-Negative Breast Cancer Patients: A Cross-Sectional Study in Indonesia
por: Halim, Freda, et al.
Publicado: (2023)

Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review
por: Halim, Freda, et al.
Publicado: (2021)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

The Correlation of KRAS Gene Expression and P53 Immunoexpression in Colorectal Adenocarcinoma
por: Rachmawati, Meike, et al.
Publicado: (2019)

Breast Self-Examination Practice and Its Determinants among Women in Indonesia: A Systematic Review, Meta-Analysis, and Meta-Regression
por: Azhar, Yohana, et al.
Publicado: (2023)

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer
por: Wu, Minhua, et al.
Publicado: (2021)

Immunoexpression of P63 and SOX2 in triple-negative breast cancers, Indonesia
por: Kamarlis, Reno K, et al.
Publicado: (2018)

MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
por: Petrelli, Annalisa, et al.
Publicado: (2020)

Testicular Epidermoid Cyst: A Rare Case Report
por: Maulana, Reza, et al.
Publicado: (2022)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers
por: Li, Qing-xia, et al.
Publicado: (2019)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

The Role of Osteocalcin and Alkaline Phosphatase Immunohistochemistry in Osteosarcoma Diagnosis
por: Agustina, Hasrayati, et al.
Publicado: (2018)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function
por: Bado, Igor, et al.
Publicado: (2018)

Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations
por: Deb, S, et al.
Publicado: (2014)

Detection of endometriosis using immunocytochemistry of P450 Aromatase expressions in eutopic endometrial cells obtained from menstrual sloughing: a diagnostic study
por: Madjid, Tita Husnitawati, et al.
Publicado: (2020)

High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-β1
por: Gipsyianti, Nastassa, et al.
Publicado: (2021)

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
por: Munzone, Elisabetta, et al.
Publicado: (2018)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review
por: Fernandes, Leonor, et al.
Publicado: (2020)

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer
por: Gandhi, Nishant, et al.
Publicado: (2021)

Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Endometriosis Menstrual Blood
por: Madjid, Tita Husnitawati, et al.
Publicado: (2020)

Comparison of Fixation Methods for Preservation Cytology Specimens of Cell Block Preparation Using 10% Neutral Buffer Formalin and 96% Alcohol Fixation in E-cadherin and Ki-67 Immunohistochemical Examination
por: Ireka, Yuke, et al.
Publicado: (2019)

Pleomorphic retroperitoneal liposarcoma with kidney infiltration mimicking renal trauma
por: El Haq, Faris, et al.
Publicado: (2021)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer
por: Davey, Matthew G, et al.
Publicado: (2023)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

Somatic mutations in early onset luminal breast cancer
por: Encinas, Giselly, et al.
Publicado: (2018)

Mutations in p53, p53 protein overexpression and breast cancer survival
por: Rossner, Pavel, et al.
Publicado: (2009)

Characterization of apoptosis and autophagy through Bcl-2 and Beclin-1 immunoexpression in gestational trophoblastic disease
por: Wargasetia, Teresa Liliana, et al.
Publicado: (2015)

The Major Role of NF-κB in the Depth of Invasion on Acral Melanoma by Decreasing CD8(+) T Cells
por: Usman, Hermin Aminah, et al.
Publicado: (2018)

CD103+ T Lymphocyte Count Linked to the Thickness of Invasion on Acral Melanoma without E-Cadherin Involvement
por: Abidin, Fauzan Ali Zainal, et al.
Publicado: (2021)

Comparison of TransPerineal Prostate Biopsy Using Novel Affordable VY Probe (TPPB-VY) and TransRectal Prostate Biopsy (TRPB) in Detection of Prostate Cancer on Hypoechoic Lesions
por: Pramod, Sawkar Vijay, et al.
Publicado: (2022)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer
por: Yamashita, Hiroko, et al.
Publicado: (2006)

Adult medulloblastoma: A rare case report and literature review
por: Faried, Ahmad, et al.
Publicado: (2016)

The largest adrenal leiomyoma: A case report and literature review
por: Pramod, Sawkar Vijay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hmjj7dj2ctpf9rginv8hg30769